Medtronic plc, a global leader in healthcare technology, has officially inaugurated a new Global Capability Centre (GCC) in Pune, India, focused on its diabetes business. Backed by an investment of $50 million over the next five years, the state-of-the-art centre is set to become a hub for innovation, digital transformation, and operational excellence. In its first year, the facility is expected to create over 300 service and software roles, with plans to double the workforce in the next four years.
For more than 40 years, Medtronic’s diabetes business has delivered groundbreaking solutions aimed at improving outcomes for people living with diabetes, allowing them greater freedom in managing their condition. The newly launched centre in Pune will further this mission by driving advancements in customer care, digital technologies, advanced analytics, patient financial services, and overall operational efficiencies.
The diabetes GCC is designed to serve as a centre of excellence, playing a critical role in enhancing global operations while creating diverse career opportunities in India’s healthcare technology sector. As the global demand for capability centres continues to rise, India has solidified its position as a leading destination. Industry reports predict that India’s GCC market could surpass $100 billion by 2030, creating over 2.5 million new jobs. Pune, in particular, has emerged as a highly attractive location due to its skilled workforce, vibrant technology ecosystem, and thriving startup culture.
“In recent years, India has firmly established itself as a global IT powerhouse,” said Que Dallara, EVP & President, Medtronic Diabetes. “The depth of talent in Pune aligns with our mission to develop solutions that simplify life for people living with diabetes. This centre represents not just growth, but a significant step forward in our commitment to expand access and improve diabetes care globally.”
Vijendra Singh, Medtronic Diabetes Global Capability Centre India Site Director and Senior Customer Service Director, added, “The launch of this centre enhances our global capabilities and reaffirms our dedication to transforming diabetes management through operational excellence. We are committed to working closely with local partners to contribute to healthcare progress while generating new talent opportunities in the region.”
This investment underscores Medtronic’s ongoing commitment to strengthening India’s healthcare and technology ecosystem. By expanding its presence in India’s growing GCC sector, Medtronic aims to boost operational efficiencies, foster innovation, and ultimately improve patient outcomes worldwide.
In parallel, Medtronic recently announced plans to spin off its diabetes business as a standalone publicly traded company named MiniMed, which is expected to begin operations as an independent entity in the near future.